Trial Profile
An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2016
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Letrozole
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms CARIATIDE
- Sponsors AstraZeneca
- 12 Oct 2010 One-year results presented at the 35th Congress of the European Society for Medical Oncology
- 24 Mar 2010 Patient number changed to 2758 from 4000 as per abstract present at 7th European Breast Cancer Conference.
- 24 Mar 2010 Trial design and baseline data presented in an abstract at the 7th European Breast Cancer Conference.